|1.||Chaisson, Richard E: 24 articles (10/2015 - 12/2002)|
|2.||Peloquin, Charles A: 19 articles (06/2014 - 09/2002)|
|3.||Grant, Alison D: 17 articles (04/2015 - 06/2005)|
|4.||Churchyard, Gavin J: 17 articles (04/2015 - 06/2005)|
|5.||Nuermberger, Eric L: 16 articles (07/2015 - 02/2004)|
|6.||Donald, P R: 15 articles (12/2011 - 06/2000)|
|7.||Karakousis, Petros C: 14 articles (01/2015 - 09/2004)|
|8.||Tuberculosis Trials Consortium: 12 articles (08/2015 - 08/2002)|
|9.||Fielding, Katherine L: 12 articles (04/2015 - 06/2005)|
|10.||Menzies, Dick: 12 articles (07/2013 - 08/2004)|
04/16/2015 - "Isoniazid is reported to be the most reliable and cost-effective remedy for tuberculosis treatment and prophylaxis among first line anti-tuberculosis drugs. "
01/01/1991 - "The parenteral administration of isoniazid in combination with other drugs was shown to be highly beneficial in disseminated form of tuberculosis in children."
05/01/1952 - "[Remarkable efficacy of isonicotinic acid hydrazide in a case of lingual tuberculosis and a case of ano-rectal tuberculosis]."
04/01/2005 - "The optimal duration of preventive therapy with single drug isoniazid, daily or twice weekly, should be greater than six months to provide the maximum degree of protection against tuberculosis. "
01/23/2014 - "Analysis of the direct effect of isoniazid in 10,909 miners showed a reduced incidence of tuberculosis during treatment (1.10 cases per 100 person-years among miners receiving isoniazid vs. 2.91 cases per 100 person-years among controls; adjusted rate ratio, 0.42; 95% CI, 0.20 to 0.88; P=0.03), but there was a subsequent rapid loss of protection. "
05/01/2013 - "This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis. "
04/01/1996 - "To compare the pharmacokinetic parameters and the clinical efficacy of isoniazid, administered in 10 mg/kg or 5 mg/kg to children suffering from pulmonary tuberculosis. "
07/13/1956 - "[Efficacy of isoniazid-PAS in pulmonary tuberculosis therapy]."
07/01/2011 - "This study was designed to characterize the population pharmacokinetics of isoniazid in South African pulmonary tuberculosis patients. "
01/01/2011 - "The aim of this study was to investigate the significance of multiple-mutations in the katG gene, predominant nucleotide changes and its correlation with high level of resistance to isoniazid in Mycobacterium tuberculosis isolates that were randomly collected from sputa of 42 patients with primary and secondary active pulmonary tuberculosis from different geographic regions of Iran. "
01/01/2005 - "According to the American Academy of Pediatrics, treatment of latent infection is highly effective with isoniazid administration for 9 months. "
06/01/1997 - "Other influences that may have diluted the efficacy of isoniazid include a high rate of transmission of new infection and rapid progression to disease or insufficient duration of isoniazid in subjects with relatively advanced immunosuppression. "
06/01/2006 - "Isoniazid preventive therapy (IPT) effectively treats latent TB infection (LTBI) and prevents progression to active TB. "
02/01/2000 - "Preventive treatment with isoniazid for 6-12 months is effective in reducing those with latent infection."
12/01/1998 - "Isoniazid is effective in the treatment of infection and prevention of progression of infection to clinical disease. "
01/01/2013 - "Patient adherence to isoniazid (INH) monotherapy for latent tuberculosis infection (LTBI) has been suboptimal despite its proven efficacy. "
09/15/2007 - "A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults. "
05/01/2010 - "Isoniazid (INH) has been the mainstay of treatment of latent tuberculosis infection for almost 50 years. "
03/05/2010 - "Since the 1960s, 6 to 9 months of isoniazid (INH) has been the mainstay of treatment for latent tuberculosis infection (LTBI), but its application has been limited by concerns about the toxicity of INH and the long duration of treatment. "
08/15/2003 - "In summary, we conclude that in our clinic population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by modest completion rates."
08/01/1999 - "The results of these studies indicated that slow inactivator of isoniazid and its epileptogenic effects might contribute to the pathogenesis of myoclonic seizures in our patient."
10/01/2015 - "We report a 20-year-old female migrant who presented with recurrent seizures after ingesting 25 g of isoniazid. "
10/01/2015 - "Isoniazid is a rare overdose that causes seizures and there is limited evidence to guide treatment. "
01/01/2015 - "Isoniazid induced convulsions at therapeutic dose in an alcoholic and smoker patient."
01/01/2014 - "This report presents a case of convulsive seizures that occurred in association with the short-term administration of a therapeutic dose of isoniazid. "
|4.||Streptomycin (Streptomycin Sulfate)
|7.||Aminosalicylic Acid (Rezipas)
|1.||Drug Therapy (Chemotherapy)
|4.||Transplantation (Transplant Recipients)